Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease
نویسندگان
چکیده
منابع مشابه
Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy.
BACKGROUND & AIMS Psoriasiform and eczematiform lesions are associated with anti-tumor necrosis factor (TNF)-α therapies. We assessed clinical characteristics, risk factors, and outcomes of skin disease in patients with inflammatory bowel diseases that presented with psoriasiform and eczematiform lesions induced by anti-TNF-α agents. METHODS We studied 85 patients (69 with Crohn's disease, 15...
متن کاملTumor necrosis factor inhibitors for inflammatory bowel disease.
n engl j med 369;8 nejm.org august 22, 2013 754 This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies, the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines, if they exist, are presente...
متن کاملGenetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients
AIM To study the type and frequency of adverse events associated with anti-tumor necrosis factor (TNF) therapy and evaluate for any serologic and genetic associations. METHODS This study was a retrospective review of patients attending the inflammatory bowel disease (IBD) centers at Cedars-Sinai IBD Center from 2005-2016. Adverse events were identified via chart review. IBD serologies were me...
متن کاملFatal infections in older patients with inflammatory bowel disease on anti-tumor necrosis factor therapy
Anti-tumor necrosis factor (anti-TNF) is highly effective in inflammatory bowel disease (IBD); however, it is associated with an increased risk of infections, particularly in older adults. We reviewed 349 patients with IBD, who were observed over a 12-month period, 74 of whom had received anti-TNF therapy (71 patients were aged <60 years and 3 were aged ≥60 years). All the 3 older patients deve...
متن کاملSystemic inflammatory profile and response to anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease
BACKGROUND Chronic obstructive pulmonary disease (COPD) is characterized by progressive worsening of airflow limitation associated with abnormally inflamed airways in older smokers. Despite correlative evidence for a role for tumor necrosis factor-alpha in the pathogenesis of COPD, the anti-tumor necrosis factor-alpha, infliximab did not show clinical efficacy in a double-blind, placebo-control...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Therapeutic Advances in Gastroenterology
سال: 2016
ISSN: 1756-2848,1756-2848
DOI: 10.1177/1756283x16638833